Clinical trials
No Disease or Condition is Being Studied clinical trials
Below are recruiting no disease or condition is being studied clinical trials, each written for real people, not researchers. We’re tracking 18,394 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT01998750Recruiting
Study of genes in severe early childhood obesity
This study looks for genetic (inherited) reasons for severe obesity that starts in very early childhood. It may help doctors better understand the cause of your child’s weight gain and guide future treatment.
Boston, MassachusettsAges Up to 80 years - NCT01720836RecruitingPhase 1/Phase 2
MUC1 peptide vaccine study for non-small cell lung cancer
This trial tests a vaccine made from a lung-cancer target (MUC1) to help your immune system recognize and fight the cancer. It is designed to measure immune response and safety, and it may help some people develop a stronger anti-cancer immune reaction.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06005818RecruitingPhase 2
MRD-guided therapy for kidney cancer after surgery
This trial tests whether personalized monitoring of cancer DNA in your blood (MRD) can guide treatment decisions after kidney cancer surgery. If MRD is detected, you may receive extra immunotherapy to reduce the risk of cancer returning.
Birmingham, AlabamaAges 18 years+ - NCT05512208RecruitingPhase 2
Avutometinib plus defactinib for RAS or BRAF mutated gynecologic cancer
This Phase 2 trial tests a two-drug treatment (avutometinib plus defactinib) for certain advanced gynecologic cancers that have specific cancer-driving DNA changes (like RAS or BRAF). It’s designed for people whose cancer has returned or gotten worse after at least one prior treatment for metastatic disease.
Orlando, FloridaAges 18–99 - NCT06096857RecruitingPhase 2
Cardamom and topical bacteria cream for eczema
This study tests whether taking cardamom by mouth and applying a cream made from a harmless bacteria (Roseomonas) can help treat eczema (atopic dermatitis) in people age 2 and older.
Bethesda, MarylandAges 2–100 - NCT06093867Recruiting
Tracking lung health after stem cell transplant
This study follows people getting a stem cell transplant to watch for lung problems, like infections or other lung diseases, that can happen after the transplant. The goal is to catch these issues early.
Bethesda, MarylandAges 5–70 - NCT06094933Recruiting
Mobile anger reduction for veterans with PTSD
This study tests a mobile app that helps veterans with PTSD manage anger. If you often feel angry or irritable, this app might help you learn ways to feel calmer and more in control.
Durham, North CarolinaAges Any age - NCT06086496Enrolling by invitation
Study of a new drug-releasing stent for heart arteries
This trial tests a new type of stent (a small mesh tube) that slowly releases a medicine called sirolimus to keep your heart artery open after angioplasty. It is designed for people with narrowing in their heart arteries who need a stent.
Seoul, SeoulAges 19 years+ - NCT06081920RecruitingPhase 2
IBI363 for advanced melanoma after standard treatment
This study tests a new drug called IBI363 for people with advanced melanoma that has progressed after standard treatment. It aims to see if IBI363 can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06090539RecruitingPhase 1/Phase 2
New drug for lymphoma that has returned or not responded
This trial tests a new drug, BMS-986458, alone or with other lymphoma treatments, for people with non-Hodgkin lymphoma that has come back or not gotten better after prior treatment.
Phoenix, ArizonaAges 18 years+ - NCT06091865RecruitingPhase 3
Testing odronextamab with chemo for untreated DLBCL
This trial is testing a new drug called odronextamab combined with chemotherapy against the standard treatment for people with previously untreated DLBCL. The goal is to see if the new combination works better and is safe.
Scottsdale, ArizonaAges 18 years+ - NCT06103864RecruitingPhase 3
Study of Dato-DXd with or without durvalumab for advanced triple-negative breast cancer
This trial is testing whether a new drug combination (Dato-DXd with or without durvalumab) works better than standard chemotherapy plus pembrolizumab for people with a certain type of advanced triple-negative breast cancer that has a protein called PD-L1. The study aims to find a more effective treatment option for this specific group.
Daphne, AlabamaAges 18 years+ - NCT06093672RecruitingPhase 3
Comparing givinostat vs hydroxyurea for polycythemia vera
This study compares a new drug called givinostat to hydroxyurea (a standard treatment) for people with polycythemia vera, a blood disorder that increases the risk of clots. The goal is to see if givinostat works better and is safe.
Birmingham, AlabamaAges 18 years+ - NCT06096116RecruitingPhase 3
Trial of a blood product for heparin resistance during heart surgery
This study tests a blood-derived medicine (antithrombin) to help people who do not respond well to the blood thinner heparin during heart surgery. It aims to make surgery safer by improving blood thinning.
Stanford, CaliforniaAges 18–85 - NCT06095089RecruitingPhase 1
Study of two drugs for advanced prostate cancer
This trial tests a new combination of two study drugs for people with advanced prostate cancer that has spread or is no longer responding to hormone therapy. The goal is to see if the combination is safe and works against the cancer.
Aurora, ColoradoAges 18 years+ - NCT06084936RecruitingPhase 3
Glofitamab alone vs other treatments for mantle cell lymphoma
This trial tests a new drug called glofitamab to see if it works better than other standard treatments for people with mantle cell lymphoma that has come back or not responded to previous therapy. It is for patients who have already tried a BTK inhibitor and at least one other treatment.
Berkeley, CaliforniaAges 18 years+ - NCT06088004RecruitingPhase 1/Phase 2
ABO2011 for advanced solid tumors (phase 1/2)
This trial tests a new investigational drug called ABO2011, which is injected directly into tumors. It is for people with advanced solid tumors that have not responded to previous treatments. The goal is to see if the drug is safe and can help shrink or slow tumor growth.
BeijingAges 18 years+ - NCT06081959RecruitingPhase 3
Study of SKB264 for advanced HR+/HER2- breast cancer
This trial tests a new drug called SKB264 for people with a common type of breast cancer (HR+/HER2-) that has spread or come back and has not responded to at least one round of chemotherapy. It aims to see if this treatment can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06095128RecruitingPhase 4
Combination therapy for ulcerative colitis
This study tests two drugs together, vedolizumab and tofacitinib, to see if they are more effective than either alone in treating moderate to severe ulcerative colitis. It may be an option if other treatments have not worked well for you.
Dothan, AlabamaAges 18–65 - NCT06102070Recruiting
Genetic study of severe infections
This study looks for genetic reasons why some people get very serious infections. If you or a family member has had a rare, severe infection, researchers will analyze your DNA to find genes that might make you more vulnerable.
Paris, Île-de-France RegionAges Any age - NCT04885179Recruiting
Study of SPLIS genetics and patient experiences
This observational study and patient registry collects information from people diagnosed with SPLIS due to specific changes in the SGPL1 gene, including children and newborns. It helps researchers understand the condition better and may improve future care and research planning.
San Francisco, CaliforniaAges Any age - NCT00221897Recruiting
Eye test study to help diagnose glaucoma
This study tests new ways to evaluate eyes to help diagnose glaucoma and related eye conditions. You may be able to join if you’re an adult with normal eye health or with concerns like myopia, glaucoma suspicion, or ocular hypertension.
La Jolla, CaliforniaAges 18 years+ - NCT06083129RecruitingPhase 3
Preventing GVHD after stem cell transplant in older adults
This trial tests two different medicines (ATG-thymoglobulin and ATLG-grafalon) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for older adults with certain blood cancers who have a matched unrelated donor.
AmiensAges 50–70 - NCT06084026Recruiting
Measuring daily activity with a small leg monitor
This study uses a small device called ActivPal clipped to your leg to measure how much you move during daily life. Researchers want to compare activity levels between people with neuromuscular disorders and healthy volunteers to better understand physical activity patterns.
New York, New YorkAges 1 year+
Hear when a new No Disease or Condition is Being Studied trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for no disease or condition is being studied?
- Yes. Clin2 currently lists 18,394 recruiting no disease or condition is being studied studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a no disease or condition is being studied trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a no disease or condition is being studied trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.